Driving Innovation, Advancing Patient-Centered Care
NorthShore is now Endeavor Health, reflecting the exciting future of our nine-hospital system and the continued growth and integration of excellent care.

Though our name may be changed, at the Endeavor Health Cancer Institute Kellogg Cancer Centers, we continue to push boundaries, offering pioneering treatment, delivering compassionate care and pursuing meaningful innovation—all in service of patients and families right here in our communities.

Providing the most advanced, personalized care to individual patients is at the core of everything we do. Our team of collaborative specialists harness state-of-the-art technology and vast experience to offer the latest therapies to improve outcomes for patients. Simultaneously we’re growing our pioneering research efforts, driving new knowledge and evidence-based clinical practices that not only help patients today, but pave the way for even better outcomes tomorrow.

Endeavor Health is playing an exciting role in a growing number of national research initiatives, building on our leadership in molecular diagnostics, genomics and more, as you’ll see in this report.

Our fellowship-trained subspecialists, multidisciplinary tumor boards, high surgical and medical oncology patient volumes, and extensive access to clinical trials ensure that our patients receive truly world-class care without having to leave their own communities.

Our academic clinicians believe in working together and value the opportunity to teach the next generation of physician leaders in our growing residency and fellowship programs. As a respected academic medical program, our clinicians and support staff remain focused on our community-connected care. New recruits from the most prestigious fellowship programs across the country choose to practice here because of the collaborative culture and the commitment to academics and excellence in patient care.

We remain incredibly grateful to the many patients and families who support our cancer program and the Kellogg Cancer Centers with philanthropic donations. Charitable donors are vital to our efforts to improve care through cutting-edge research, and donations are also essential to our many patient support programs. We thank each and every donor whose support makes a meaningful difference in the lives of countless patients.

While we offer comprehensive care for the full range of cancers, including the most complex and rare cases, this report highlights just a few areas of exciting new innovation. We thank you for your interest in our mission of patient-centered, community-focused excellence.

Bruce Brockstein, MD  
Medical Director, NorthShore Kellogg Cancer Center  
Division Head, Hematology/Oncology  
Kellogg-Scanlon Chair of Oncology

Seth Krantz, MD  
Division Head, Thoracic Surgery  
Chairman, NorthShore Cancer Committee
Collaborative Surgical Interventions for Complex Cases

Endoscopic endonasal skull base surgery uses tiny cameras to navigate the nasal sinuses in order to access the base of the skull and remove tumors and malignancies deep in the brain. This unique approach allows for the minimally invasive treatment of complex tumors through a natural opening—the nose—that would otherwise require large incisions and prolonged recoveries.

Over the last decade, the fellowship-trained team of neurosurgeon Ricky Wong, MD, and otolaryngologist Joseph Raviv, MD, have developed a uniquely collaborative and successful skull base program that allows them to tackle even the most complex cases. “It takes each of our skill sets working together to accomplish these surgeries,” said Dr. Raviv. Each case begins with an incredible amount of planning and advanced imaging that enables the surgeons to meticulously detail the steps of the procedure from getting to and removing tumors to reconstructing the skull base.

Using their different perspectives to achieve a common goal over the course of hundreds of cases has resulted in tremendous patient outcomes. This synergy creates efficiency that translates into shorter procedure times, fewer complications and faster recovery. Many of our patients go home within a day of their surgery.

Beyond technical expertise, Drs. Wong and Raviv share a common philosophy and approach to patient care. “We really connect with all our patients,” said Dr. Wong. “When I need to make decisions intraoperatively, I always think what would I want if this were me. Every fraction of a millimeter makes a difference in the periphery of these tumors in terms of brain function, nerves and the chance a cancer can come back.” This philosophy has kept the skull base team at the forefront of innovation and has drawn neurosurgeons and otolaryngologists from across the country to NorthShore’s Grainger Center for Simulation and Innovation to be trained in these techniques.
Jennifer Kehoe was midway through her first pregnancy in late summer 2020 when she started feeling very congested. A couple months later, she began experiencing severe nose bleeds and eventually was unable to breathe through her right nostril.

She made an appointment with expert otolaryngologist and skull base surgeon Joseph Raviv, MD, but still was not overly alarmed. “He knew from the moment he looked at me that it was serious,” said Kehoe. “I tend to be a nervous person around medical things and I feel so fortunate I ended up with him. I developed a trust with him that first day.”

Kehoe’s trust was well-placed as Dr. Raviv and neurosurgeon Ricky Wong, MD, have built an exceptional, collaborative program for endoscopic skull base surgery to remove malignancies in the sinuses, nasal cavities and parts of the brain near the sinuses.

Dr. Raviv performed multiple biopsies on the mass in Kehoe’s nose. The results were terrifying as she soon learned she had an aggressive cancer. “Everything after that happened very quickly,” she recalled. Dr. Raviv and Dr. Wong presented the complex case to the Kellogg Cancer Center tumor board and consulted with NorthShore’s Maternal-Fetal Medicine team for high-risk pregnancies. Comprehensive, multidisciplinary planning led to the right approach for Kehoe and her baby.

Together, the team decided she should deliver the baby first and then have surgery to remove the tumor. At 35 weeks, Kehoe gave birth to a healthy 7-pound, 9-ounce baby at NorthShore Evanston Hospital. Three days later, she was transferred to the operating room to have the tumor removed on her 37th birthday.

The surgery was even more complex than anticipated, but the tumor was fully removed through her nose. “I am forever grateful for the amount of work they did and that they were able to go through my nose,” said Kehoe. Pathology revealed that the margins around the tumor were clean, which was a huge relief as Kehoe focused on healing before beginning radiation and chemotherapy under the guidance of medical oncologist Bruce Brockstein, MD and radiation oncologist Vathsala Raghavan, MD.

“Dr. Brockstein, Dr. Raghavan, Dr. Wong and Dr. Raviv worked seamlessly as a team for me, and they all had my trust,” recalled Kehoe. “I truly believed they knew what to do for me.”

Kehoe is now close to three years of being cancer-free following her surgery, and her son Teddy is a very smart and funny toddler who loves preschool and dogs.

“Every time I see her, she brings me a new photo of her son,” said Dr. Raviv. “This is why we do what we do. Cases and patients like this are the reason we practice.”

“Her story really highlights what we’re able to do, approaching each patient as a person, not just a disease process,” said Dr. Wong. “I believe our patients see us as more than just their surgeons, and we definitely see them as more than cases.”

“I feel very fortunate to have the team I did,” said Kehoe. “Dr. Raviv, Dr. Wong, Dr. Raghavan and Dr. Brockstein are all very highly skilled and gifted doctors—but even more so, they’re extraordinary people. They made me feel like family throughout this whole experience and not just like my doctors. I will be forever grateful for all of them.”
Exciting advances in the treatment of both early and advanced rectal cancer are offering patients dramatic improvements in quality of life. Kellogg Cancer Center’s Rectal Cancer Program Director Monika Krezalek, MD, is leading multidisciplinary efforts incorporating the latest evidence-based new treatment and surveillance protocols for rectal cancer patients.

Dr. Krezalek is pioneering the latest approach in robotic, minimally invasive surgery for early rectal cancers. The traditional low anterior resection approach for these cancers is major surgery that often results in a temporary or permanent ostomy for patients. Up to 60% of patients undergoing the major surgery have lasting symptoms that negatively affect their quality of life, including significant changes in bowel habits such as difficulty emptying, urgency, frequency and soiling, explained Dr. Krezalek. This substantial operation also carries the risk of pelvic nerve injury that can result in urinary and sexual dysfunction.

Offering patients with early rectal cancers the new and less invasive approach of robotic transanal minimally invasive surgery (R-TAMIS) has been revolutionary. Dr. Krezalek published her study on the approach in Diseases of the Colon & Rectum and has been a leader in the promising trend of organ preservation in early rectal cancer.

Treatment trends for locally advanced rectal cancers include total neoadjuvant chemoradiotherapy (TNT) and “watch and wait” protocols when a complete clinical response to TNT is followed by close surveillance rather than the traditional course of major pelvic surgery. In many instances, this translates to avoiding a permanent colostomy in patients with low rectal cancers. Additionally, clinical trials have demonstrated TNT protocols are superior to conventional approaches of chemoradiation and adjuvant chemotherapy in terms of higher rates of complete clinical response, less toxicity and longer rates of survival.

“Most patients are devastated by the news of having cancer,” said Dr. Krezalek. “These new treatment protocols offer them more options and hope for better quality of life once treatment is complete.” Dr. Krezalek acknowledged that surgery remains an important treatment modality for many patients with advanced rectal cancers.

All rectal and colon cancer patients are presented at regular tumor board sessions involving surgeons, medical oncologists, radiologists, pathologists and radiation oncologists, and cases are thoroughly reviewed by the collaborative team to determine the best individual approaches to care.

Prestigious NAPRC Accreditation on the Way

Kellogg Cancer Center is in the process of joining an elite group of organizations recognized by The American College of Surgeons National Accreditation Program for Rectal Cancer (NAPRC) this year. Spearheaded by Dr. Krezalek, the accreditation process reflects the program’s commitment to the latest evidence-based gold standard treatments and multidisciplinary care.

Currently, there are just 82 NAPRC-accredited programs in the United States, with only seven in Illinois. “NAPRC accreditation efforts reflect the commitment of our multidisciplinary team to provide evidence-based quality care to our rectal cancer patients,” said Dr. Krezalek.
When her internist suggested a screening colonoscopy for Mary (who asked that her real name not be used), the 49-year-old thought, “Better safe than sorry.” She’s now thinking, “If I had waited, who knows what would have happened?”

Two days after her first colonoscopy, Mary received a call that one of the rectal polyps removed during her colonoscopy showed she had cancer. She was referred to colon and rectal surgeon Monika Krezalek, MD, and further diagnostics including an MRI, CAT scan and blood work confirmed that the cancer was very early.

“I was shocked, but hopeful,” said Mary. “It was fortuitous to find it early.”

Meeting Dr. Krezalek was also a positive. “She was very helpful and walked my husband and me through all the options,” said Mary. “She even encouraged us to get a second opinion.” After meeting with another physician at a regional academic medical center, Mary was confident that Dr. Krezalek was the right choice.

An expert in transanal minimally invasive surgery, Dr. Krezalek was hopeful that Mary’s cancer could be removed with robotic transanal minimally invasive surgery (TAMIS), avoiding major surgery and the associated risks and changes to quality of life. She explained that she wouldn’t know for sure whether Mary would be able to avoid major surgery until the mass was removed and assessed by a pathologist under the microscope.

Dr. Krezalek was able to successfully perform the robotic TAMIS excision in an outpatient procedure, and Mary was home a few hours later. On review by the pathologist, the cancer was in fact very early, confirming that surveillance could be undertaken instead of the major rectal resection.

“I had the surgery on a Thursday and was back to work by Monday. I never even took the pain medicine that was prescribed,” said Mary, who now undergoes cancer surveillance every three months with blood work and rotating MRIs, CAT scans and ultrasounds as well as exams with Dr. Krezalek.

“I feel strong and optimistic about my future,” said Mary, who enjoys spending time with her family and two grandchildren.

“I am so grateful Dr. Krezalek is my doctor,” said Mary. “She’s super knowledgeable, caring and honest, and I feel really fortunate to be her patient. You can tell that she really cares about you and your health.”

“It’s very gratifying to take care of patients like Mary and offer these minimally invasive procedures that treat the cancer and help preserve their quality of life,” said Dr. Krezalek.
Increasing Immunotherapy Treatment Innovations

Kellogg Cancer Center first introduced checkpoint inhibitor immunotherapy when medications became available through clinical trials, and we remain ahead of the curve in offering immunotherapy as a pioneering form of treatment for many types of cancers.

The recent introduction of CAR T-cell therapy has been transformative for lymphoma patients. One of the first non-university-based, certified CAR T-cell treatment programs in the state, the Kellogg Cancer Center initiative is led by hematologist David Grinblatt, MD. The pioneering, FDA-approved therapy is the best new option for patients with relapsed or refractory lymphoma, offering game-changing benefits for those whose disease was not responsive to other treatments.

In-house expertise in managing CAR T-cell patients will help pave the way for offering other innovative treatments. FDA-approved cellular therapies are available for many blood cancers and are on the horizon for many solid tumor malignancies. Today, more than one-third of Kellogg Cancer Center patients are treated with immunotherapy medications.

Our immunotherapy program involves a comprehensive, collaborative team of specialists across a range of disciplines with experience in helping manage side effects and optimizing overall wellness.
First CAR T-Cell Patient Thriving

Mick Jackson first battled lymphoma six years ago with surgery and chemotherapy under the expert guidance of NorthShore hematologist Lynne Kaminer, MD. “I had a lot of faith in her and was very confident I would be cured,” said Jackson, who was indeed in remission until he faced an atypical late relapse last September.

It’s more common for high-grade lymphoma to come back in the first two to three years,” explained Dr. Kaminer. “In Jackson’s case, his relapse was extensive with cancer in his bone marrow, liver and lymph nodes.”

After undergoing chemotherapy, it was clear the 74-year-old retired computer programmer was not a good candidate for a stem cell transplant. However, CAR T-cell treatment—pioneering, FDA-approved therapy and the new gold standard for patients like Jackson—proved to be a very promising option.

Dr. Kaminer explained that Jackson would be NorthShore’s first CAR T-cell patient in the new program led by hematologist David Grinblatt, MD. Then she walked him and his wife through the protocol, including potential side effects.

“I gave her the go-ahead the next day,” said Jackson. “I had total trust in her.”

CAR T-cell therapy involves chimeric antigen receptor (CAR) genetically modified T cells (a type of immune cells) that are designed to recognize and activate specific tumor cell molecules to destroy malignant cells. Patients’ own immune cells are collected in a process similar to dialysis, engineered to fight the cancer cells, and are then given back to the patient, harnessing the body’s own immune system to attack cancer.

Jackson spent 11 days in Evanston Hospital when he received the CAR T infusions and was closely monitored by a multidisciplinary team of specialists well versed in the major side effects of the treatment. “All of the nurses at Kellogg were wonderful,” he said. “As a rule, I really don’t like medicine and hospitals, but this all worked out so well for me.”

After several weeks of feeling very tired, Jackson began to regain his strength. Soon he was back to his active lifestyle including regular exercise, cycling, philosophy classes, reading and writing.

“It’s very gratifying to care for patients and know that we can offer these innovative therapies,” said Dr. Kaminer, who is hopeful about future applications for CAR T and growing numbers of bispecific therapies for lymphoma and other cancers.

A negative PET scan six months post-treatment confirmed that Jackson is now cancer-free. “I’m confident I have many years ahead of me,” he said.
Expanded Treatment Options for Bladder Cancer

Innovative treatment options for advanced and metastatic bladder cancer patients are offering new hope for people for whom other therapies have failed. New immunotherapy drugs, neoadjuvant chemotherapy and post-cystectomy options are among the advanced treatment offerings at Kellogg Cancer Center’s growing program for urologic cancer.

“We are seeing up to 70% response rates with the latest immunotherapy drugs for advanced bladder cancer patients,” said lead urologic oncologist Kristian Novakovic, MD. In the last two years, the options for treatment of this often devastating disease have dramatically expanded, as has our program. Urologic oncologist Craig Labbate, MD, who did his residency at the University of Chicago and fellowship at MD Anderson Cancer Center, joined the team last year.

Kellogg Cancer Center patients have access to the latest medications through clinical trials; the most advanced robotic, computer-assisted and minimally invasive surgical techniques; and tri-modal therapy with chemo, radiation and surgery. Fellowship-trained surgeons and oncologists work collaboratively with multidisciplinary specialists to assess individual patients and, where appropriate, offer more conservative approaches to treatment. While bladder removal remains the gold standard treatment for invasive cancers, it can be a quality of life altering event, said Dr. Novakovic. Our ability to perform robot-assisted, nerve-sparing surgery and advanced bladder substitutions can help protect sexual and urinary function.

We continue to expand our program for managing all urologic malignancies, especially bladder cancer. Dedicated nurse navigators for genitourinary cancer patients are helping streamline the patient experience and create more seamless communication with all related specialists. An Enhanced Recovery After Surgery (ERAS) protocol for bladder cancer is in the works joining our existing protocol for prostate cancer. Specially trained nurses help with all facets of patient education, particularly preparing for surgery and, when necessary, adapting to life with a urinary tract stoma. Patients also have access to sexual health nurse practitioners to aid in their recovery of sexual function following surgery. Our goal is to leverage the strengths of NorthShore as a community health system, providing the most advanced care available.

Cardio-oncology Center of Excellence

Joining just 26 other hospital systems in the country and earning gold status recognition from the International Cardio-Oncology Society (IC-OS), NorthShore was awarded the prestigious IC-OS Center of Excellence Designation.

Led by Jason Robin, MD, our cardio-oncology program has grown dramatically since its inception in 2019 and was recognized by IC-OS for its “exceptionally high concentration of expertise and related resources” to provide the best patient outcomes. Dr. Robin and the cardio-oncology team have published more than 20 peer-reviewed manuscripts; are collaborating with Massachusetts General Hospital in the pioneering ATRIUM clinical trial related to evaluating and managing myocarditis in patients receiving immunotherapy; and have developed numerous quality improvement projects that impressed the IC-OS review committee.

Rupa Patil, MD, Tariq Azam, MD, and Amit Pursnani, MD, join Dr. Robin as key members of the cardio-oncology clinical team, providing highly specialized heart care for patients with cancer. The potential risk of cardio-toxicity from cancer treatment puts cancer patients at an increased risk of developing certain cardiovascular conditions. Prevention and early intervention are key to limiting cardiac complications that can interfere with essential cancer treatments.

“This honor recognizes a true team effort and reflects the fact that our patients can trust that they are receiving the most advanced cardiovascular care,” said Dr. Robin.
NorthShore was involved in one of two major randomized Phase III, placebo-controlled trials that have shown that adding immunotherapy to standard chemotherapy significantly increases benefits for patients with advanced and recurrent endometrial cancer.

“It’s exciting to finally have this new standard of care for advanced and recurrent endometrial cancers,” said gynecologic oncology specialist Tilley Jenkins Vogel, MD. “Having these drugs available in the frontline setting will be a game-changer for patients.” Kellogg Cancer Center patients involved in the trial are still on the protocol, and the results have been phenomenal, added Dr. Jenkins Vogel.

Both studies were published in The New England Journal of Medicine in March 2023 and each demonstrated “significantly longer progression-free survival” with the addition of an immunotherapy drug to chemotherapy treatment.

Many other trials are in the pipeline, promising other new therapeutic options. “It's an exciting time in the field, and everything is moving so fast,” said Dr. Jenkins Vogel. “There are a lot of maintenance therapies on the horizon, and there may be some patients who won’t need chemotherapy.”

For example, a large, international Phase III trial is currently underway looking at the use of combination therapy with a checkpoint inhibitor (pembrolizumab) plus a multikinase inhibitor (lenvatinib) as first systemic treatment in patients with advanced and recurrent endometrial cancers—cohorts who have historically been treated with traditional chemotherapy as the standard of care.

While there are certain endometrial cancer subgroups that will predictably respond to immunotherapy based on their specific molecular subtype/profile, the most common endometrial cancer subtype responds much less robustly to checkpoint inhibitor therapy. For that group, which accounts for a majority of endometrial cancer patients, effective front- and later-line treatment and maintenance options are currently lacking. Dr. Jenkins Vogel is serving as the institutional principal investigator for yet another major multi-site post-chemotherapy maintenance trial with a novel oral agent for advanced and recurrent endometrial cancer patients who do not have a biomarker for response to immunotherapy.

Progress in molecular profiling is helping drive new therapies for patients with endometrial and other gynecologic cancers who have previously had limited options.

Dr. Jenkins Vogel was a co-author on another clinical trial presented this year that demonstrated positive results using targeted combination therapy for a rare subgroup of ovarian cancer patients. Enrollment of NorthShore patients in this pivotal study contributed to these practice-changing results.

A robust clinical trial portfolio is just one element of Kellogg Cancer Center’s strong gynecologic oncology program, long recognized for leadership in clinical care and promising research related to ovarian and endometrial cancers.
A lung cancer screening event held at Highland Park Hospital in September was part of Kellogg Cancer Center’s ongoing mission to raise awareness of and access to vital, lifesaving screening for those at higher risk of developing lung cancer.

Feedback from participants was incredibly positive, and 21 people were scheduled for low-dose CT scans following the event. At least one person was sent on for further diagnostics after the scan.

The use of CT scans for people at high risk for developing lung cancer has been linked to a dramatic 20% reduction in lung cancer deaths. The screening is now covered by Medicare and insurance for patients who meet the risk criteria, yet too few of those eligible for screening are actually having the scans.

Individuals who currently smoke, or who have quit within the last 15 years and who are 50 to 80 years old are encouraged to consider the screening. Current guidelines suggest annual screening for people with a 20 pack-year history of smoking—a pack year equals smoking one pack per day for a year, smoking two packs a day counts as two pack years and so on.

NorthShore was an active participant in the International Early Lung Cancer Action Program (I-ELCAP) and has been a longtime advocate for increased screening for those at elevated risk.

“We are working to underscore the importance of screening as a way to catch cancer sooner when it’s far more treatable,” said Seth Krantz, MD, Head of Thoracic Surgery and chairman of the NorthShore Cancer Committee. “The scan rates for eligible patients, those at higher risk of developing lung cancers, are still very low locally and nationally.”

---

**Breast Cancer Program Recognized for Excellence**

Our breast health program was recognized for a high level of achievement and providing excellent care by the National Accreditation Program for Breast Centers (NAPBC), a quality program of the American College of Surgeons (ACS). Citing a rich history and an array of strengths, NAPBC granted the program reaccreditation.

Nursing competency, genetics and an emphasis on personalized medicine and patient education were some of the strengths highlighted in the accreditation survey.

Katharine Yao, MD, Director of Breast Cancer Research, chairs the national ACS NAPBC leadership committee, and Catherine Pesce, MD, is our NAPBC Breast Surgical Program Director.

---

**National Recognition for Oncology Program**

NorthShore – Edward-Elmhurst Health was named to Becker’s Hospital Review’s 2023 list of “100 hospitals and health systems with great oncology programs. “The system’s multidisciplinary, subspecialty care model and collaborative team approach to patient care” was noted in the listing, as was our partnership with the University of Chicago Pritzker School of Medicine and academic and research activities.

The Review also notes “The Kellogg Cancer Center offers pioneering techniques through Kellogg Cancer Genomic Initiative to help identify, diagnose and treat diseases. The Center was also an early adopter of immunotherapy to treat advanced cancer.”
Innovative Research Driving Clinical Excellence

Accelerating Innovation with CancerX

NorthShore – Edward-Elmhurst Health (NS-EEH) was recognized for a unique ability to innovate and implement, like its pioneering approach with genomics and prevention and screening in primary care. A founding member of the CancerX public-private partnership, NS-EEH is one of only two Illinois entities represented in this pioneering collaboration.

CancerX focuses on commoditizing best practices and aligning incentives; coordinating access to research, mentorship, resources and other collaborative opportunities; and demonstrating success in practice to drive broad adoption—all with an eye toward reducing the incidence and burden of cancer.

“It’s exciting to play a role in this ambitious project to accelerate scientific discovery and care in cancer,” said Peter Hulick, MD, The Janardan D. Khandekar, MD, Chair of Personalized Medicine and Medical Director of Mark R. Neaman Center for Personalized Medicine. “We have a history of being able to implement at the bedside in a very nimble way, and we believe our strengths related to genomics and digital health solutions will help advance the effort.”

The inaugural project for the partnership is “advancing digital innovation to improve equity and reduce financial toxicity in cancer treatment.”

NS-EEH joined other prominent health systems and biotech companies as founding members of President Joe Biden’s Cancer Moonshot initiative working to develop cures for cancer. President Biden reignited the Cancer Moonshot project with an impressive goal of cutting the U.S. cancer death rate by at least 50% in the next 25 years. To accelerate the development of treatments and cures and boost innovation in the fight against cancer, the Biden administration launched CancerX in March 2023.

Accelerating Innovation with CancerX

Dr. Jianfeng Xu, DrPH, Vice President of Translational Research, has led efforts using genomic data to improve cancer detection, treatment and patient outcomes.
Education Highlights

Breast Cancer Surgical Fellowship

A one-year Breast Surgical Oncology Fellowship Program in partnership with NorthShore and the University of Chicago Medicine continues to draw a growing group of highly qualified candidates, gaining national recognition for clinical, educational and research excellence.

Led by Catherine Pesce, MD, Program Director for the Breast Surgical Oncology Fellowship, the fellowship is in its third year and has successfully matched a fellow for next year’s program.

“The success of the program speaks to the high quality of our team of breast surgeons and the large volume of breast cancer cases,” said Dr. Pesce. The Kellogg Cancer Center’s fellowship-trained surgeons offer expertise and training in the most advanced techniques including nipple-sparing mastectomies and oncoplastic breast surgery. “We are one of the few sites in the country participating in a clinical trial for robotic nipple-sparing mastectomies,” added Dr. Pesce.

“This has been a really great experience,” said current fellow Callie McAdams, MD. “The system has everything a patient needs to receive great care—great surgeons, oncologists, plastic surgeons, radiation oncologists, emotional psychosocial support, a survivorship program and more.”

Dr. McAdams said one of the draws of the fellowship for her was the large and varied patient population ranging from benign simple cases to the most complex. “I feel like I’m getting a very well-rounded surgical training, and the way everybody teaches here has helped inform how I want to shape my own practice,” said Dr. McAdams. “If my aunt or mom had breast cancer, I would be glad to have them come here for care. That says a lot about the program.”

The most common feedback Dr. Pesce and colleagues hear from fellows is that they’d like to stay on staff, she said, noting that last year’s fellow has joined the oncology team at Edwards-Elmhurst Health.

Oncology Resident Elective

Kellogg Cancer Center faculty continue to draw rave reviews from residents who benefit from working with experienced clinicians with a shared commitment to academic excellence. Residents rotate through different oncologic subspecialties in the outpatient clinics, gaining a thorough overview of each type of malignancy, explained Oncology Resident Program Director Britt Hanson, DO.

Residents rotating through the oncology elective are provided reading material regarding specific malignancies and work one-on-one with an oncologic physician seeing patients in the clinical setting. The residents also see oncology patients in the inpatient setting to provide additional educational value. Additionally, residents attend cancer-specific tumor boards to discuss patient cases in a multidisciplinary manner.

“The strength of our program reflects our team’s desire to help train the next generation of leaders in medicine,” said Dr. Hanson. The goal of the oncology elective is to give the resident a broad, in depth understanding of oncologic knowledge that they can rely on for the rest of their career.
Thanks in part to our many generous donors, the Kellogg Cancer Center is able to provide patient- and family-centered care. In addition to an ongoing focus on prevention, early detection and advanced treatment options for cancer, we are also committed to offering patients and families a full range of resources to help navigate and manage their cancer journey.

From emotional and spiritual support to special nutritional guidance, integrative medicine services, assistance with practical needs like transportation or financial aid, and a robust survivorship program, the extended Kellogg Cancer Center team delivers comprehensive, compassionate support.

Comprehensive Support Services

Integrative Oncology Clinic
Kellogg Cancer Center patients now have the opportunity to meet one-on-one with an Integrative Oncology (IO) Nurse Practitioner at the IO clinic at the Evanston Hospital site. The program provides for an initial evaluation with ongoing follow-up visits, and patients can be seen at any time from diagnosis to treatment through survivorship.

IO Nurse Practitioners Sara Reynolds and Maggie Keller each completed a year-long IO Scholars Program funded by the National Cancer Institute at the University of Michigan and have extensive experience working with oncology patients.

Keller and Reynolds work collaboratively with the oncology clinical team and offer evidence-based complementary therapies incorporating natural products, mind and body practices, lifestyle modifications, and nutrition designed to help patients enhance their health and overall wellbeing.

The IO Nurse Practitioners are working with patients with a wide variety of cancer types to help them achieve better sleep, manage stress, improve daily living, and offset or decrease challenging symptoms from cancer treatments.

“The patients are really appreciative that Kellogg provides this service,” said Reynolds. “It’s empowering for patients to focus on themselves, and it’s been gratifying for us to be able to help them prioritize and optimize their overall health while going through their cancer journey,” added Keller.

The IO Nurse Practitioners partner with NorthShore’s robust Integrative Medicine Program and appreciate the many resources that are available for patients.

Enhanced Navigation
Having a consistent presence from the day of diagnosis through various stages of treatment and into survivorship benefits patients in what can be an all-consuming effort. Our specially trained, compassionate nurse navigators provide this important frontline support for patients, and we’re working to further enhance the navigation process. Additional nurse navigators and social workers are coming together collaboratively to refine our efforts to seamlessly guide patients through the entirety of this challenging time.
Since its inception, philanthropy has been a critical aspect of Kellogg Cancer Center’s success. The Center was established, in part, by a very generous gift from the Kellogg family more than 40 years ago. Today, donor support is even more essential to helping physicians, nurses and the entire clinical team deliver exceptional, personalized care to every patient. From employing the latest novel treatments and access to cutting-edge clinical trials, to providing a full range of unique support services, none of this could be possible without community investment.

The fast pace of change in treating cancers and new discoveries is a positive reality. More people are beating cancer than ever before thanks to exciting advancements in research and a commitment by physicians to harness the power of the body’s own immune system. There are more options delivering better outcomes and brighter futures. Our donors bolster our clinical team members’ ability to serve every patient and break down the barriers to care for all—regardless of their ability to pay. Generous philanthropy has helped make Kellogg Cancer Center a trusted community resource when people need it most.

Helping Patients Reduce Hair Loss

Hair loss is one of the most feared and common side effects of chemotherapy, and its emotional impact can add to the trauma of cancer treatment. The Paxman Scalp Cooling System® offers a treatment that can prevent hair loss caused by certain chemotherapy drugs. Scalp cooling has been most effective for patients undergoing certain chemotherapy regimens for early-stage breast cancer.

Kellogg Cancer Center now has a liaison who works directly with patients using the scalp cooling system. A former patient, the Paxman liaison works with our breast cancer collaborative nurses and is able to offer hands-on support. Patients continue to express gratitude for the scalp cooling system and the experience of working with someone who understands what they’re going through.

Patient Financial Assistance

Our experienced Patient Financial Advocates are available to help patients navigate insurance coverage and medical bills. They can also help access and determine eligibility for our financial assistance program and philanthropy-funded patient assistance grants.

Specific patient assistance grants are generously funded by donors and are used to help patients in need with medical bills, medications and other related costs. Requests for these grants have continued to rise since the pandemic and continued economic challenges for many individuals and families.

Kellogg Cancer Center is committed to removing barriers for essential, lifesaving care.

Vital Philanthropic Support

To learn more about how you can support Kellogg Cancer Center, please call Kevin Gray in the NorthShore Foundation at 224-364-7609. Or visit foundation.northshore.org

Dr. Janardan D. Khandekar, the founding Head of the Division of Medical Oncology

For more information, visit northshore.org/cancer or call (847) 570-2112 or scan the QR code on the back cover.
2023 Clinical Trials

Breast Cancer
EA1181 Compass (HER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
A011801 The CompassHER2 trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib
S2007 A Phase II Trial of Sacituzumab Govitecan (MMU-132) for Patients with HER2-Negative Breast Cancer and Brain Metastases
CCTG MA.39: Tailor RT A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer

Gastrointestinal Cancer
NRG-GI004/SWOG-S1610 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer
UC14-0594 Perioperative FOLFIRINOX: A Pilot Trial of Perioperative Genotype-Guided Irinotecan Dosing of mFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma
NRG-GI008 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)

Genitourinary Cancer
Johns Hopkins J1557 Overcoming Drug Resistance in Metastatic Castration-Resistant Prostate Cancer with Novel Combination of TGF-β Receptor Inhibitor LY2157299 and Enzalutamide: A Randomized Multi-Site Phase II Study
NRG-GU008 A Randomized Phase III Trial Incorporating Aribatereone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE)
EA8183 A Phase III Study of Early Intervention After RADICAL ProstateTectomy with Androgen Deprivation Therapy with Darolutamide Versus Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
UC13-0540 Atezolibib (BIBW 2992) in Advanced Refractory Urothelial Cancer
S1806 Phase III Randomized Trial of Concurrent Chemoradiationtherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer
CURLu177PSM0001 A Multi-Center, Open-Label, Randomized Phase III Trial Comparing the Safety and Efficacy of 111Lu-PSMA-617 Versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Myovant Relugolix Versus Leuprolide in Patients with Prostate Cancer: A Randomized, Open-Label Study to Assess Major Adverse Cardiovascular Events (REPLACE-CV)
EA8212-A Randomized Phase III Trial of Intravesical BCG Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG Naive High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)
UC20-0736 A Feasibility Study of Education About an Alternative to Chronic LHRH Agonist or Antagonist Therapy in Patients with Prostate Cancer
S2011 Randomized Phase II Trial of Gemcitabine, Avelumab and Carboplatin Versus No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma
SWOG GAP Trial Genomic Profiling and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer

Gynecologic Cancer
AGCT1531 A Phase III Study of Active Surveillance for Low-Risk and a Randomized Trial of Carboplatin Versus Cisplatin for Standard-Risk Pediatric and Adult Patients with Germ Cell Tumors
GOG-3026 A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum NRG-GY020: Randomized Phase III Trial of Radiation +/- MK-3475 (Pembrolizumab) for Newly Diagnosed Early-Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer (NCT# 04214067)
NRG-CC008 A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers (SOROCK)
NRG-GY019 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
NRG-GY022 Assessment of carboplatin clearance predictors: a PK study on NCI-sponsored clinical trials or standard of care treatments using carboplatin
GOG3073-CORT125124-556 A Phase III Study of Relacloriant in Combination with Nab-Paclitaxel Versus Nab-Paclitaxel Monotherapy in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal or Fallopian-Tube Cancer (ROSELLA)
GOG 3066-ZN-c3-005 A Phase II Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NRG-GY026 A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oxys (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2-positive, Stage I-IV endometrial serous carcinoma or carcinosarcoma
A092104 A Randomized Phase II/III Study of Olaparib Plus Temozolomide Versus Investigator’s Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma After Progression on Prior Chemotherapy
GOG 3065/ZN-c3-004 A Phase II, Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma

For more information about clinical trials, visit northshore.org/kellogg-cancer-center/clinical-trials
Head and Neck Cancers

**HCN** Tissue bank tissue/body fluid procurement and clinical data collection for patients with malignancies of the head and neck area and/or premalignant changes

**NRG HN005** A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking-Associated Oropharyngeal Cancer

**RT06 1216** Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

**Mercik:** MK-7902-009-05 Phase II, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitor) (LEAP-009)

**Hematology**

**Connect**™ MDS/AML The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

**CIBMTR** Research database for hematopoietic cell transplantation, other cellular therapies and marrow toxic injuries

**A041501** A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (ages 18-39) with Newly Diagnosed Precursor B-Cell Acute Lymphoblastic Leukemia

**EAA173** Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

**S1925** Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study

**EA9181** A Phase III Randomized Trial of Steroids + TKI Induction with Chemotherapy or Blinatumomab for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL) in Adults

**S1918** A Phase II/II randomized study of R-miniCHOP with or without CC-486 (oral azacitidine) in patients age 75 years or older with newly diagnosed diffuse large B-cell lymphoma, Grade III follicular lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements (NCT04799275)

**A Pilot Study** Assessing Neurocognitive Impairments in Adult Survivors of Adolescent and Young Adult Hematologic Malignancies

**Lung Cancer**

**Lung-MAP** A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously Treated Non-Small Cell Lung Cancer

**E4512** A Phase III double-blind trial for surgically resected early-stage non-small cell lung cancer: Crizotinib versus placebo for patients with tumors harboring the anaplastic lymphoma kinase (ALK) fusion protein

**A151216** Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

**EA5181** Randomized Phase III Trial of MED14736 (Duvralumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

**A081801** Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO (ACCIO)

**S1900E** A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer

**S2302** Non-Chemotherapy Treatment (Ramucirumab Plus Pembrolizumab) or Usual Care for Advanced Non-Small Cell Lung Cancer Following Immunotherapy

**Neuro-Oncology**

**NRG BN003** Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

**A071702** A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

**NCI-Connect Nivolumab Rare CNS Trial 17-C-0102** Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers

**Brain-Up/U of C** A Phase I Study of Safety and Tolerability of Acetazolamide with Temozolomide in Adults with Newly Diagnosed MGMT Wildtype Glioblastoma

**Sarcoma**

**Ayala AL-DES-01 (Ringside)** A Phase II/III, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

**A092107** A Randomized Phase II Trial with a Safety Lead-In to Evaluate Palbociclib versus Palbociclib and Cemiplimab for the Treatment of Advanced Dedifferentiated Liposarcoma

**Skin Cancer**

**EA6141** Randomized Phase II/III study of nivolumab plus ipilimumab plus sargramostim versus nivolumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma

**Other**

**Carevive OPT-IN®** Real-World Treatment Experience of Patients with Breast, Lung, Multiple Myeloma, Acute Myelogenous Leukemia or Ovarian Cancer Using Remote Symptom Monitoring

**A151904** Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

**Genomic Panels** Prospective Analysis of the Utility of Routine Incorporation of Genomic Panels into the Care of Patients with Metastatic Cancer

**ANTHOS 8** A multicenter, randomized, open-label, blinded endpoint evaluation, phase III study comparing the effect of abeculinab relative to datelparin on venous thromboembolism (VTE) recurrence and bleeding in patients with gastrointestinal (GI)/genitourinary (GU) cancer associated VTE (Magnolia)

**Anthos 7** A multicenter, randomized, open-label, blinded endpoint evaluation, Phase III study comparing the effect of abeculinab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
**Surgical Oncology Trials**

**Breast Surgery**
- **EH20-166** The Ergonomic Effects of the Robotic Nipple Sparing Mastectomy on the Operating Surgeon
- **EH20-165** Exploring Breast Surgical Oncologists’ Attitudes and Comfort Level with Universal Genetic Testing
- **EH15-297** A randomized Phase III trial comparing axillary lymph node dissection to axillary radiation in breast cancer patients (cT1-3 N1) who have positive sentinel lymph node disease after neoadjuvant chemotherapy

**Colorectal Surgery**
- **EH12-468 N1048** A Phase II/III trial of neoadjuvant FOLFOX with selective use of combined modality chemoradiation versus preoperative combined modality chemoradiation for locally advanced rectal cancer patients undergoing low anterior resection with total mesorectal excision

**Head and Neck Surgery**
- **EH17-116** Lipid Tissue from Head and Neck Cancer

**Pancreatic Cancer**
- **EH18-265** A Phase III Multicenter, Open-Label, Randomized, Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreato-duodenectomy
- **EH08-197T** Clinical pancreatic cancer database
- **EH13-433** Comprehensive Assessments for Clinical Care and Surgical Management Among Individuals with Pancreatic Pathology
- **EH02-186** The Pancreatic Sample Repository

**Lung and Esophageal Cancer**
- **EH17-132** Assessment of Tumor and Treatment Factors as Predictors of Venous Thromboembolism in Patients with Pancreatic Adenocarcinoma Undergoing Pancreato-duodenectomy, and Efficacy of Pharmacologic Prophylaxis

**Thyroid Surgery**
- **EH14-058** The establishment of a multidisciplinary comprehensive database of patients for thyroid nodular disease

**Genitourinary Cancer**
- **EH09-043** A multi-phase study of active surveillance for men with clinical stage T1c or T2a localized prostate cancer

For more information about clinical trials, visit northshore.org/kellogg-cancer-center/clinical-trials


Pesce CE. Donor Egg Surrogacy and Adoption for Breast Cancer Survivors. *Current Breast Cancer Reports*. 2023 Feb:15;24-29


Raviv J, Sweis A. Survey of In-Office Rhinology and Skull Base Questionnaires. Accepted in 11/2022. ARS COSM. May 2023


For more information, visit northshore.org/cancer or call (847) 570-2122 or scan the QR code on the back cover. Page 19

continued >


Kellogg Cancer Center clinicians are active in a broad range of regional and national organizations.

Sameer Alvi, MD
- American Head & Neck Society—Member, Young Members Service
- American Head & Neck Society—Member, Website and Social Media Service
- Peer Reviewer, Annals of Otology, Rhinology and Laryngology
- Poster Presentation:
  - Utility and Validity of Preoperative Positron Emission Tomography (PET) in Localizing Perforator Vessels of Anterolateral Thigh Free Flap.

Bruce Brockstein, MD
- Member, Head and Neck Committee, Eastern Cooperative Oncology Group
- Editorial:
  - UpToDate (Online Textbook), Chapter Editor, Head and Neck Cancer, 2000–present
- Awards:
  - Chicago Magazine Top Doctors

Nicholas Campbell, MD
- Editorial:
  - NHPCO (National Hospice and Palliative Care Reviewer:
  - Advisory Board, American Liver Foundation,
  - Poster Presentation:
    - Dermatology Lead, Family Medicine Lecture Series

Nisha Desai, MD
- Dermatology Lead, Family Medicine Lecture Series
- Poster Presentation:

Claus Fimmel, MD, CPE
- Advisory Board, American Liver Foundation, Chicago Chapter, 2008-present
- Editorial:

Nancy Flowers, LCSW
- NHPCO (National Hospice and Palliative Care Organization); Member of the NHPCO Executive Committee and Section Leader, MyNHPCO Social Work Community; presented at NHPCO’s annual Leadership and Advocacy Conference in October 2022 and October 2023
- Guest lecturer, Loyola University School of Social Work
- Other community education: Cancer Wellness Center, NorthShore Senior Center, CJE Senior Life, Lutheran Home, others
- Board Membership: Bishop Anderson House, Three Crowns Park (past Board Chair for both)

David Grinblatt, MD
- Community Oncology Committee, ALLIANCE for Clinical Trials in Oncology, 2010-present
- Principal Investigator, Alliance for Clinical Trials in Oncology
- Scientific Advisory Committee, Connect MDS/AML Registry and Connect* Lympoma Disease Registry

Brian Helfand, MD, PhD
- Guideline Review Committee for American Urological Association Prostate Cancer Early Detection
- Guidelines Committee Member: American Urological Association Overactive Bladder
- American Urological Association North Central Research Committee
- Established race-specific genetic testing for prostate cancer in collaboration with GoPath Diagnostics
- Principal Investigator: Blue Earth Diagnostics Study on PSMA Imaging Techniques
- Principal Investigator: NanaKnife IRE PRESERVE trial (focal therapy for prostate cancer)
- Grand Rounds: Changes in imaging techniques for Prostate Cancer Staging and Recurrence: UCSD, Invited Speaker
- Current Updates in Prostate Cancer and Support Group
- Grand Rounds in Urology Series: Prostate cancer imaging—a patient discussion

Thomas Hensing, MD
- Respiratory Health Association, Lung Cancer Initiative Advisory Council, 2005-present
- ALLIANCE for Clinical Trials in Oncology, Respiratory Committee Member, 2010-present
- CoC/NCCB Lung Quality Measures Group, 2011-Present
- Respiratory Health Association, Invited Member, Scientific Advisory Committee, 2019-Present

Melissa Hogg, MD
- Education Council (2020-present), Chair (2022-2024), Executive Council (2023-2026)—SSO (Society of Surgical Oncology)
- Membership Committee (2020-2023)—SUS (Society of University Surgeons)
- Alliance Executive Board Liaison (2020-2023), CSSP Representative (2023-present)—AHPBA (American Hepato-Pancreato-Biliary Association)
- HPB Task Force (2017-present), Co-Chair (2019-present), Oncology Task Force (2020-present)—SAGES (Society of American Gastrointestinal and Endoscopic Surgeons
- Fellowship Council—HPB working group representing SAGES (Society of Gastrointestinal and Endoscopic Surgeons)

Awards:
- Distinguished Alumni Award, U Pitt Medical Education, 2023
- University of Chicago—Teaching Award, 2022-2023

Invited Lectures:
- “Resident Robotic Training: The Past, The Present, The Future” Grand Rounds @ SUNY April 2023
- “Video-Based Assessment: Eliminating Bias” Women in Surgery Career Symposium, Clearwater, FL. February 2023
- “Regrettable Decisions: MIS” AHPBA March 11, 2023, Miami, FL
- “MIS Biliary Updates” March 12, 2023, Miami, FL
- “Career Panel: Community vs. Academic Practice” SSO March 22, 2023, Boston, MA
- “Advanced Simulation Based Training Program for Robotic Surgery: Robotic Pancreatoduodenectomy” Mayo Robotic Conference April 15, 2023, Orlando, FL
- “DGE – Professor Talk” DDW May 8, 2023, Chicago, IL
- “How We Educate Our Fellows” SSAT-SAGES Joint Symposium, May 8, 2023
- “Surgical Education: Robotics, Simulation, and Beyond,” Northwell Medical School Curriculum ReCamp, May 2023
- “Robotic Pancreatododenectomy: Oncologic Outcomes and Clinical Trials.” CSSP September 2023. Chicago IL
- “Pancreatoduodenectomy Reconstruction Masterclass,” LEARNBOT Europe April 11, 2023

For more information, visit northshore.org/cancer or call (847) 570-2112 or scan the QR code on the back cover.
Peter J. Hulick, MD, MMSc, FACMG
• American College of Medical Genetics and Genomics representative on the CancerLinQ Oncology Leadership Council for ASCO
• Epic Genetics and Genomics Steering Board Member
• Member—Personalized Medicine Coalition Public Policy Committee
• Member—Personalized Medicine Coalition Science Policy Committee
• Director on the American Board of Medical Genetics and Genomics

Awards:
• Newly appointed as the Janardan D. Khandekar MD, Chair of Personalized Medicine, NorthShore University Health System

Poster Presentation:
• Hulick P, Choi S, Dunnenberger H, DePersia A. Integrating Family Health History Screening and Genetic Testing via Electronic Health Record with Clinical Decision Support in Routine Screening Mammography. Poster presentation at the American College of Medical Genetics and Genomics Meeting, Nashville, TN, 2022

Presentations:
• 2022: Panelist: “Precision Medicine—Beyond the “One-Size-Fits-All” Model.” Kellogg Business of Healthcare Conference, Evanston, IL
• 2022: Lessons Learned from Virtual Genetic Counseling. Precision Medicine World Conference 2022, Silicon Valley, CA
• 2022: “Population Genetic Screening Efforts in Primary Care.” Precision Oncology and Diagnostics Conference, Chicago, IL
• 2023: “Improving Access to Genetics Through Primary Care.” AGBT Precision Health Meeting, San Diego, CA

Amanda Silver Karcigliu, MD
National Committees:
• Patient Care and Education Committee of the American Head and Neck Society—Endocrine Surgery Section
• Scientific Review Committee for 11th International Conference on Head & Neck Cancer, July 8-12, 2023 in The Palais des Congrès, Montréal, QC Canada

National Presentations:
• Great Debate: Is Parathyroid Autofluorescence the New Operative Standard for Thyroid Surgery? (Presenter), AAO-HNSF 2023 Annual Meeting and Oto Experience Nashville, TN, September 30-October 4, 2023
• Parathyroid Gland Identification: More Than Meets the Eye(Presenter), AAO-HNSF 2023 Annual Meeting and Oto Experience Nashville, TN, September 30-October 4, 2023
• Surgical Recurrent Laryngeal Nerve Variability and Risk of Injury (Presenter), AAO-HNSF 2023 Annual Meeting and Oto Experience Nashville, TN, September 30-Oct 4, 2023

Karen Kaul, MD
National Committees:
• American Board of Pathology: Appointed Trustee, 2011-present, Chair, Test Development & Advisory Committee for Molecular Genetics, 2012-present, Maintenance of Certification Committee, 2012-present, Credentials Committee, 2012-present, Communications Task Force, 2012-present
• Association for Molecular Pathology: Chair, MGP Curriculum Update (MGPUP) committee, 2019-present, AMP COVID Response (ACR) Steering Committee, 2020-present, Member, JMD Editor in Chief Selection Committee, 2021-present
• College of American Pathologists: Member, Executive Advisory Board, Archives of Pathology & Laboratory Medicine, 2015-present
• Association of Pathology Chairs: Chair, ad hoc Clinical Service Leaders Council, 2021-present, Vice Chair, Advocacy Committee, 2021-present

Scientific Review Activities:
• Ad Hoc Member, NIH/NCI P01 reviewer, 2001-present, SBIR Review Panels, various, 2008-present; Panel chairperson 2010-present; Peer Reviewer, Prostate Cancer Foundation, 2010-present; Peer Reviewer, University of Chicago CTSA Pilot Program, 2011-present; Chair, NorthShore Auxiliary Breast/Ovarian Research Program, 2013-present

Other National Activities:
• Lab 2.0 Board Member, 2019-present
• Member, CLIA CLIA Regulations Assessment Workgroup, 2021-present

Editorial:
• Ad Hoc Reviewer: American Journal of Clinical Pathology, Archives of Pathology and Laboratory Medicine, Cancer, Cell Growth and Differentiation, Chest, Clinical Chemistry, Clinical Microbiology Reviews, Pediatric Pathology, Tuberce, 1990-present
• Editorial Board, Annual Reviews in Pathology, 2011-present
• Associate Editor, Academic Pathology, 2014-present
• Executive Advisory Board, Archives of Pathology & Laboratory Medicine, 2015-present

Invited Talks:
• Realizing the Potential of Genomics Across the Continuum of Precision Health Care. National Academy of Science, Engineering and Medicine, Roundtable on Genomics and Precision Health, Speaker and panelist.

Margaret Keller, APN
• Completed the University of Michigan’s Integrative Oncology Scholars program, June 2022

Poster Presentation:
• “The Time Is Now: Creating a Nurse-Practitioner-Led Integrative Oncology Clinic” at the Society of Integrative Oncology’s annual conference, Banff, Alberta, Canada in September 2023
Janardan D. Khandekar, MD
Editorial:
- Associate Editor, Journal of Surgical Oncology
- Reviewer, PLOS Medicine and Journal of Clinical Oncology
Grants:
- Anonymous FDN to sequential study titled “Immune Response to COVID Vaccination in Cancer Patients”
Honors:
- NorthShore has established The Janardan D. Khandekar, MD, endowed chair in Personalized Medicine in honor of Dr. Khandekar. This Chair recognizes the extraordinary 46-year legacy of Dr. Khandekar, who as the founder of the Division of Medical Oncology, Director of the NorthShore Kellogg Cancer Center for 25 years, and the Louise W. Coon Chairman of Medicine for 13 years has led the way to creating today’s program in genomics.

Katherine Kopens, MD
- Vice President, Chicago Surgical Society
- Oncoplastic Committee, American Society of Breast Surgeons
- Principal investigator for the FDA-reviewed national trial “A Prospective, Multicenter Investigation of the da Vinci® Xi™ Surgical System in Nipple-Sparing Mastectomy (NSM) Procedures”

Awards:
- Alpha Omega Alpha Beta Chapter Class of 2023 at the Pritzker School of Medicine Volunteer Clinical Faculty Award, 2023
- Castle Connolly Top Doctor, 2023
- University of Chicago Excellence in Teaching Award from the Department of Surgery for 2018-19, 2020-2021, 2021-2022, 2022-2023 academic years
- NorthShore University HealthSystem Service Values Award 2018-present (26-time award winner, nominated for exceptional performance earning customer loyalty)

Seth Krantz, MD
- Chair, NorthShore University HealthSystem Cancer Committee
- Head, Division of Thoracic Surgery
- Clinical Associate Professor of Surgery, University of Chicago Pritzker School of Medicine
- Society of Thoracic Surgeons, Health Policy and Advocacy Task Force Member
- American College of Surgeons Cancer Research Program Standards Investigation and Validation Committee Member
- Site PI, surgical research cooperative of the American Association for Thoracic Surgery
- Site PI for Prolonged Air Leak Autologous Blood Patch Intervention Trial

Awards:
- Outstanding Cancer Liaison Physician Award, American College of Surgeons Commission on Cancer
- University of Chicago Department of Surgery Excellence in Teaching Award 2022-2023

Editorial:

Robert Marsh, MD
- Eastern Cooperative Oncology Group, GI Committee

Editorial:

Leslie Mendoza Temple, MD
- Co-Chair of the Oversight Committee for the International Research Congress for Integrative Medicine and Health, to be held in Cleveland, Ohio, in April 2024
- Co-investigator for an international Delphi study on Competency-Based Medical Education (CBME) for healthcare professionals on the subject of cannabis education for trainees with Mikhail Kogan, MD (George Washington University), Richard Isralowitz, PhD, and Yuval Zolotov, PhD (both from Ben-Gurion University of the Negev in Israel)
- Member, Medical Cannabis Advisory Board, Illinois Department of Public Health

Catherine E. Pesce, MD
- Head, Division of Surgical Oncology
- Society of Surgical Oncology (SSO) Breast Surgical Oncology Fellowship Program Directors Committee

Leadership Awards:
- American Society of Breast Surgeons (ASBrS) Online Video Library
- Excellence in Teaching Award from the University of Chicago Department of Surgery for 2021-2022
- Breast Surgical Oncology Fellow Anna Chichura, MD, won the 2022 ASBrS Annual Meeting “Outstanding Scientific Presentation Award for the Best Presentation by a Fellow, Resident or Medical Trainee” for her oral podium presentation: “Male Breast Cancer Patient and Surgeon Experience: The Male WhySurg Study”

Committees:
- American Society of Breast Surgeons (ASBrS) Online Video Library Committee
- Society of Surgical Oncology (SSO) Breast Surgical Oncology Fellowship Program Directors Committee, 2021-present

Presentations:
- NorthShore Foundation Powered by Giving Event, “Personalized Medicine and Genomics as Ways to Make Breast Health and Cancer Screening Unique.” Wilmette, IL., 2023
- American Society of Breast Surgeons Annual Meeting, “Goldilocks Mastectomy: ASBrS Video Presentation How I Do It.” Boston, MA, 2023

Joseph Raviv, MD
- Chicago Laryngological & Otological Society—Immediate Past President
- American Rhinologic Society (ARS)—Rhinology Training Council, Co-Director Annual ARS Advanced Sinus and Skull Base Course
- Chicago Magazine Top Doctors

Sara Reynolds, APN
- Completed the University of Michigan’s Integrative Oncology Scholars program, June 2022

Poster Presentation:
- “The Time Is Now: Creating a Nurse-Practitioner-Led Integrative Oncology Clinic” at the Society of Integrative Oncology’s annual conference, Banff, Alberta, Canada in September 2023

Gustavo Rodriguez, MD
- Member, Cancer Prevention and Control Committee, Gynecologic Oncology Group/NRG, 1997-present
- Advisory Board, Gilda’s Club, Chicago, 2004-present

Editorial:
- Peer Reviewer, American Journal of Obstetrics & Gynecology, Current Cancer Drug Targets, Gynecologic Oncology, Journal of Clinical Oncology
- Peer Reviewer, Journal of Clinical Oncology

Presentations:
- Advances in Complex Thyroid Surgical Care (Presenter), Department of Medicine Grand Rounds, NorthShore University HealthSystem, Evanston, IL, April 21, 2023
- Advances in Complex Thyroid and Parathyroid Surgical Care (Presenter), Department of Medical Oncology Grant Rounds, NorthShore University HealthSystem, Evanston, IL, July 27, 2023

Carol Rosenberg, MD
- Mentor, Scholars in Oncology Associated Research Program (SOAR) at the University of Chicago Pritzker School of Medicine covering multidisciplinary and inter-professional aspects of oncology (cancer) research and clinical care. NIH/NCI grant 1R25CA240134-01
- Key Informant, Johns Hopkins University Evidence-Based Practice Center (EPC) and the Agency for Healthcare Research and Quality (AHRQ) Topic Refinement and Realist Reviewer on "Models of Pediatric-Adolescent-Adult Cancer Survivorship Care that include Primary Care"
- Reviewer, ASCO Journal of Clinical Oncology (JCO) Oncology Practice
- Research Investigator/Topic Reviewer, Women’s Health Initiative Study, National Institutes of Health (NIH NHLBI)

Awards:
- Myra Rubenstein Weis LIFE Program Grant Award Recipient to the MRW LIFE Cancer Survivorship program: Myra Rubenstein Weis Health Resource Center Foundation NorthShore University HealthSystem May, 2023

For more information, visit northshore.org/cancer or call (847) 570-2112 or scan the QR code on the back cover.
Poornima Saha, MD
Poster Presentations:

Awards:
- 2023 NorthShore Women’s Cancers Research Program: Concept/Pilot Award Recipient — Dr. Poornima Saha for project entitled “Artificial Intelligence for Response Prediction in Breast Cancer.”

Principal Investigator:
- EA1181: CompassHER2-pCR: Preoperative THP and postoperative HP in patients who achieve a pathologic complete response
- A011801: The CompassHER2 trials (COMprehensive use of Pathologic Response Assessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, Phase III randomized trial of T-DM1 and placebo compared with T-DM1 and letrozole.
- S2007: A Phase II Trial of Sunitinibum GS/tecan (IMMU-132) (NSC #620016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

Akhil Seth, MD
- Residency Site Director, Plastic and Reconstructive Surgery Residency, University of Chicago

Clinical Trials:
- Principal Investigator: The Safety and Effectiveness for Durastor for Lower Pole Reinforcement in Patients Undergoing 2-Stage Breast Reconstruction

Daniel Shevrin, MD
- Community Co-Chair, ECOG GU Committee, 2005-present
- Medical Director, NorthShore Chapter of US TOOP Prostate Cancer Support Group, 2002-present
- Director, Advocacy Core Prostate SPOR, Northwestern University, 2003-present

Mark Sisco, MD, FACS
- Program Committee, Breast Subsection, American Society of Plastic Surgeons, 2015-present
- Editorial Board Member and Peer Reviewer, Journal of Surgical Oncology, 2014-present
- Peer Reviewer, Journal of Surgical Research, Plastic and Reconstructive Surgery

Mark Talamonti, MD
- Ex Officio Member, Medical Advisory Committee, PanCAN, Pancreatic Cancer Action Network, 2010-present
- High Risk GI Committee, member, American College of Surgeons Committee on Patient Safety and Improved Quality, 2018-present
- Chairman, Department of Surgery, NorthShore University HealthSystem, 2007-present

Awards:
- Outstanding Faculty Teacher Award, Department of Surgery, University of Chicago Pritzker School of Medicine
- Castle and Connelly and Chicago Magazine Top Doctors in America and Chicago
- US News and World Report: Top 1% of Surgeons in America
- National Pancreas Foundation 2023 Legacy Award

Amy Wang, MD
- Fellowship Director, Division of Hematology/Oncology, NorthShore University HealthSystem

Presentations:
- Oral Presentation abstract #670: “New Oncotarget Neurocognitive Impairment in Long-Term Survivors of Early Adolescent and Young Adult Hematologic Malignancies: A Report From the Childhood Cancer Survivor Study.” 65th ASH Annual Meeting, San Diego, CA, December 2023
- Poster Presentation abstract #3776: “Improved Neurocognitive Outcomes with Contemporary Treatments in Survivors of Early Adolescent and Young Adult Hematologic Malignancies from the Childhood Cancer Survivor Study.” 65th ASH Annual Meeting, San Diego, CA, December 2023

Lauren Wiebe, MD
- American College of Surgeons Cancer Research Program Standards Investigation and Validation Committee Member
- TPN in Cancer Patients Working Group, NorthShore, 2023-present
- Editorial:
- Invited Peer-Reviewer: Journal of Palliative Medicine, 2021-2023

Katharine Yao, MD
- Member, ASCO-SSO Germline Mutation Testing in Breast Cancer Guideline Panel
- Practice Advocacy Committee, American Society of Breast Surgeons
- Member, Prevention Committee of the Alliance
- Chair, Breast Disease Site Group Quality Measures, Commission on Cancer
- Chair, National Accreditation Program for Breast Centers
- Chair, Benign Breast Pathway Steering Group, American Society of Breast Surgeons
- Member, Commission on Cancer Executive Committee
- Member, Executive Committee on Surgical Standards, Commission on Cancer, American College of Surgeons
- Co-Moderator, Management of Hormone Receptor Positive Breast Cancer in the Elderly, American College of Surgeons Clinical Congress, Boston, MA, October 2023
- Breast Cancer Research Foundation, Precision Prevention Initiative Grant Review Panel
- American Cancer Society National Breast Cancer Roundtable, Workgroup member for Risk Reduction, Screening and Early Detection Priority Workgroup

Awards:
- Masters in Healthcare Quality and Patient Safety, Northwestern University, June 2023

Editorial:
- Journal of Surgical Oncology, Annals of Surgical Oncology, Annals of Breast Surgery

Grants:
- Mindfulness intervention and response to stress and quality of life in patients diagnosed with breast cancer. John Wayne Cancer Foundation Grant Award. Recipient, Principal Investigator: Yao K
- Developing Digital Pathology for Breast Cancer Recurrence, Department of Defense Grant. Principal Investigator: Huo D (UofC). Site Principal Investigator: Yao K
2023 Physician Directory

<table>
<thead>
<tr>
<th>Name</th>
<th>Specialties</th>
<th>Locations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Adess, MD</td>
<td>Medical Director, Highland Park Kellogg Cancer Center; Expertise: GI Oncology; Benign and Malignant Hematology</td>
<td>GBK, HPK</td>
</tr>
<tr>
<td>Marc Alonzo, MD</td>
<td>Expertise: Interventional Radiology</td>
<td>EH, GB, HP, SK</td>
</tr>
<tr>
<td>Sameer Alvi, MD</td>
<td>Expertise: Head and Neck Cancers; Thyroid/Parathyroid Surgery; Microvascular Reconstruction; Transoral Robotic Surgery</td>
<td>GBK, HPK</td>
</tr>
<tr>
<td>Hassan Arshad, MD</td>
<td>Expertise: Head and Neck Cancer; Microvascular Reconstruction; Transoral Robotic Surgery</td>
<td>EVK, NMB, SW</td>
</tr>
<tr>
<td>Tariq Azam, MD</td>
<td>Expertise: Cancer-Related Cardiotoxicity; Cancer-Treatment Related Cardiotoxicity; General Cardiology; Preventive Cardiology; Cardiovascular Disease; Cardiac Imaging</td>
<td>VH</td>
</tr>
<tr>
<td>Julian Bailes, MD</td>
<td>Chair, Department of Neurosurgery Co-Director; NorthShore Neurological Institute Expertise: Brain Tumors; Brain Disorders; Aneurysms; Spinal Disorders; Epilepsy Surgery; General Neurosurgery</td>
<td>EV, HPH</td>
</tr>
<tr>
<td>William Bloomer, MD</td>
<td>Chair, Department of Radiation Oncology Expertise: Breast Cancer; Prostate Cancer; Lung and Gastrointestinal Cancer</td>
<td>EH, HPH</td>
</tr>
<tr>
<td>Bruce Brockstein, MD</td>
<td>Division Head, Hematology/Oncology, Medical Director, Kellogg Cancer Center; Kellogg-Scanlon Chair of Oncology Expertise: Head and Neck Cancers; Melanoma; Sarcoma</td>
<td>EVK, HPK</td>
</tr>
<tr>
<td>Elizabeth Burke, MD</td>
<td>Expertise: Breast and Facial Reconstruction Including Facial and Breast Reconstruction; Microsurgery; Skin Cancer; Aesthetic Breast and Body Surgery</td>
<td>NMS, SW</td>
</tr>
<tr>
<td>Nicholas Campbell, MD</td>
<td>Expertise: Lung Cancer; Esophageal Cancer; Head and Neck Cancers</td>
<td>EVK, HPK, SW</td>
</tr>
<tr>
<td>Caroline Soto Chervin, MD</td>
<td>Expertise: Lung Cancer; GI Oncology</td>
<td>EVK, HPK</td>
</tr>
<tr>
<td>Shakeel Chowdhry, MD</td>
<td>Expertise: Surgery for Aneurysms; Endovascular Treatment for Aneurysms; Anterovenous Malformations (AVMs); Interventional Stroke Therapy; Brain Tumors; Pituitary Tumors; Spinal Tumors</td>
<td>EV, GB, NCH</td>
</tr>
<tr>
<td>John Cieslak, MD</td>
<td>Expertise: Interventional Radiology</td>
<td>EH, GB, HP, SK</td>
</tr>
<tr>
<td>Jeffrey Cilley, MD</td>
<td>Medical Director, Swedish Hospital Cancer Center, President of Medical Staff, Swedish Hospital Expertise: Benign and Malignant Hematology; Medical Subspecialty: Breast Oncology</td>
<td>Location: SW</td>
</tr>
<tr>
<td>Peter Colegrove, MD</td>
<td>Expertise: Sexual Dysfunction; Incontinence; Prostate Health; Kidney Stones; Vasectomy</td>
<td>EV, GB</td>
</tr>
<tr>
<td>Allison DePersia, MD</td>
<td>Expertise: Hematology Oncology; High Risk Breast Cancer</td>
<td>Location: EV</td>
</tr>
<tr>
<td>Nisha Desai, MD</td>
<td>Expertise: Adult and Pediatric Dermatology; General Dermatology; Laser and Surgical Treatment of Birthmarks; Herniogia</td>
<td>Locations: MP, SK</td>
</tr>
<tr>
<td>Thomas Farrell, MD</td>
<td>Expertise: Interventional Radiology</td>
<td>EH, GB, HP, SK</td>
</tr>
<tr>
<td>Alla Gimelfarb, MD</td>
<td>Medical Director, Kellogg Cancer Center Immediate Care Expertise: Benign and Malignant Hematology</td>
<td>Location: GBK</td>
</tr>
<tr>
<td>Thomas Farrell, MD</td>
<td>Expertise: Interventional Radiology</td>
<td>EH, GB, HP, SK</td>
</tr>
<tr>
<td>Carol Campbell, MD</td>
<td>Expertise: Lung Cancer; Esophageal Cancer; Head and Neck Cancers</td>
<td>EVK, HPK, SW</td>
</tr>
<tr>
<td>Tariq Azam, MD</td>
<td>Expertise: Cancer-Related Cardiotoxicity; Cancer-Treatment Related Cardiotoxicity; General Cardiology; Preventive Cardiology; Cardiovascular Disease; Cardiac Imaging</td>
<td>VH</td>
</tr>
<tr>
<td>Hassan Arshad, MD</td>
<td>Expertise: Head and Neck Cancer; Microvascular Reconstruction; Transoral Robotic Surgery</td>
<td>EVK, NMB, SW</td>
</tr>
<tr>
<td>Sameer Alvi, MD</td>
<td>Expertise: Head and Neck Cancers; Thyroid/Parathyroid Surgery; Microvascular Reconstruction; Transoral Robotic Surgery</td>
<td>GBK, HPK</td>
</tr>
<tr>
<td>Hassan Arshad, MD</td>
<td>Expertise: Head and Neck Cancer; Microvascular Reconstruction; Transoral Robotic Surgery</td>
<td>EVK, NMB, SW</td>
</tr>
<tr>
<td>Tariq Azam, MD</td>
<td>Expertise: Cancer-Related Cardiotoxicity; Cancer-Treatment Related Cardiotoxicity; General Cardiology; Preventive Cardiology; Cardiovascular Disease; Cardiac Imaging</td>
<td>VH</td>
</tr>
<tr>
<td>Julian Bailes, MD</td>
<td>Chair, Department of Neurosurgery Co-Director; NorthShore Neurological Institute Expertise: Brain Tumors; Brain Disorders; Aneurysms; Spinal Disorders; Epilepsy Surgery; General Neurosurgery</td>
<td>EV, HPH</td>
</tr>
<tr>
<td>William Bloomer, MD</td>
<td>Chair, Department of Radiation Oncology Expertise: Breast Cancer; Prostate Cancer; Lung and Gastrointestinal Cancer</td>
<td>EH, HPH</td>
</tr>
<tr>
<td>Bruce Brockstein, MD</td>
<td>Division Head, Hematology/Oncology, Medical Director, Kellogg Cancer Center; Kellogg-Scanlon Chair of Oncology Expertise: Head and Neck Cancers; Melanoma; Sarcoma</td>
<td>EVK, HPK</td>
</tr>
<tr>
<td>Elizabeth Burke, MD</td>
<td>Expertise: Breast and Facial Reconstruction Including Facial and Breast Reconstruction; Microsurgery; Skin Cancer; Aesthetic Breast and Body Surgery</td>
<td>NMS, SW</td>
</tr>
<tr>
<td>Nicholas Campbell, MD</td>
<td>Expertise: Lung Cancer; Esophageal Cancer; Head and Neck Cancers</td>
<td>EVK, HPK, SW</td>
</tr>
<tr>
<td>Sameer Alvi, MD</td>
<td>Expertise: Head and Neck Cancers; Thyroid/Parathyroid Surgery; Microvascular Reconstruction; Transoral Robotic Surgery</td>
<td>GBK, HPK</td>
</tr>
<tr>
<td>Hassan Arshad, MD</td>
<td>Expertise: Head and Neck Cancer; Microvascular Reconstruction; Transoral Robotic Surgery</td>
<td>EVK, NMB, SW</td>
</tr>
<tr>
<td>Tariq Azam, MD</td>
<td>Expertise: Cancer-Related Cardiotoxicity; Cancer-Treatment Related Cardiotoxicity; General Cardiology; Preventive Cardiology; Cardiovascular Disease; Cardiac Imaging</td>
<td>VH</td>
</tr>
<tr>
<td>Julian Bailes, MD</td>
<td>Chair, Department of Neurosurgery Co-Director; NorthShore Neurological Institute Expertise: Brain Tumors; Brain Disorders; Aneurysms; Spinal Disorders; Epilepsy Surgery; General Neurosurgery</td>
<td>EV, HPH</td>
</tr>
<tr>
<td>William Bloomer, MD</td>
<td>Chair, Department of Radiation Oncology Expertise: Breast Cancer; Prostate Cancer; Lung and Gastrointestinal Cancer</td>
<td>EH, HPH</td>
</tr>
<tr>
<td>Bruce Brockstein, MD</td>
<td>Division Head, Hematology/Oncology, Medical Director, Kellogg Cancer Center; Kellogg-Scanlon Chair of Oncology Expertise: Head and Neck Cancers; Melanoma; Sarcoma</td>
<td>EVK, HPK</td>
</tr>
<tr>
<td>Elizabeth Burke, MD</td>
<td>Expertise: Breast and Facial Reconstruction Including Facial and Breast Reconstruction; Microsurgery; Skin Cancer; Aesthetic Breast and Body Surgery</td>
<td>NMS, SW</td>
</tr>
<tr>
<td>Nicholas Campbell, MD</td>
<td>Expertise: Lung Cancer; Esophageal Cancer; Head and Neck Cancers</td>
<td>EVK, HPK, SW</td>
</tr>
<tr>
<td>Sameer Alvi, MD</td>
<td>Expertise: Head and Neck Cancers; Thyroid/Parathyroid Surgery; Microvascular Reconstruction; Transoral Robotic Surgery</td>
<td>GBK, HPK</td>
</tr>
<tr>
<td>Hassan Arshad, MD</td>
<td>Expertise: Head and Neck Cancer; Microvascular Reconstruction; Transoral Robotic Surgery</td>
<td>EVK, NMB, SW</td>
</tr>
<tr>
<td>Tariq Azam, MD</td>
<td>Expertise: Cancer-Related Cardiotoxicity; Cancer-Treatment Related Cardiotoxicity; General Cardiology; Preventive Cardiology; Cardiovascular Disease; Cardiac Imaging</td>
<td>VH</td>
</tr>
<tr>
<td>Julian Bailes, MD</td>
<td>Chair, Department of Neurosurgery Co-Director; NorthShore Neurological Institute Expertise: Brain Tumors; Brain Disorders; Aneurysms; Spinal Disorders; Epilepsy Surgery; General Neurosurgery</td>
<td>EV, HPH</td>
</tr>
<tr>
<td>William Bloomer, MD</td>
<td>Chair, Department of Radiation Oncology Expertise: Breast Cancer; Prostate Cancer; Lung and Gastrointestinal Cancer</td>
<td>EH, HPH</td>
</tr>
<tr>
<td>Bruce Brockstein, MD</td>
<td>Division Head, Hematology/Oncology, Medical Director, Kellogg Cancer Center; Kellogg-Scanlon Chair of Oncology Expertise: Head and Neck Cancers; Melanoma; Sarcoma</td>
<td>EVK, HPK</td>
</tr>
</tbody>
</table>

For more information, visit northshore.org/cancer or call (847) 570-2112 or scan the QR code on the back cover.
Cecylia K. Mizera, MD
Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery
Location: SW

Catherine Pesce, MD
Division Head, Surgical Oncology
Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery
Locations: EV, HP

Jason Robin, MD
Expertise: Cardio-Oncology
Location: GB

Tricia Moo-Young, MD
Expertise: Minimally Invasive Approaches to Endocrine Disorders; Thyroid and Parathyroid Surgery; Adrenal Disorders; Cancer and Disease Management
Locations: HPH, SK

Nicklaus Pfanzelter, MD
Expertise: Genitourinary Cancer, Prostate Cancer, Melanoma
Locations: EVK, GBK, HPK

Gustavo Rodriguez, MD
Division Head, Gynecologic Oncology
Expertise: Gynecologic Oncology
Location: EVK

Elena Moore, MD
Expertise: Gynecologic Oncology
Locations: EVK, HPK

Elizabeth Poli, MD
Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery
Locations: GB, HPB, VH

Carol Rosenberg, MD
Director, Preventive Health Initiatives; Director, Myra Rubenstein Weis Living in the Future (LIFE) Cancer Survivorship Program
Expertise: Cancer Survivorship
Location: HPH

Joseph Muldoon, MD
Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancer; Inflammatory Bowel Disease; General Surgery
Locations: EV, GB

Ariel Polish, MD
Expertise: GI Oncology; Benign and Malignant Hematology; Lung Cancer
Locations: EVK, GBK, GR

Akhil Seth, MD
Expertise: Breast Reconstruction; Aesthetic Breast and Body Surgery; Oncologic Reconstruction
Location: NMB

Ranjeev Nanda, MD
Expertise: Stereotactic Radiosurgery; Head and Neck Cancers; Prostate Cancer; Prostate; Prostate
Locations: EH, GBH

Vathsala Raghavan, MD
Expertise: Thyroid Cancer; Breast Cancer; Gynecologic Oncology; Head and Neck Cancers
Locations: EH, GBH, HPH

Arif Shaikh, MD
Expertise: Stereotactic Radiosurgery; Head and Neck Cancers; Lung Cancer; Gynecologic and Breast Tumors; Prostate
Locations: EH, GBH

Kristian Novakovic, MD
Expertise: Bladder Cancer; Kidney Cancer; Prostate Cancer; Minimally Invasive Techniques: Laparoscopy and da Vinci Robot
Locations: EV, GB

Joseph Raviv, MD
Division Head, Otolaryngology
Expertise: Nasal and Sinus Surgery; Endoscopic Skull Base Surgery
Locations: NMB, SK, SW

Daniel Shevrin, MD
Medical Director, Glenbrook Kellogg Cancer Center
Expertise: Prostate Cancer; Gynecotumary Cancer
Locations: EVK, GBK

Sangtae Park, MD, MPH
Expertise: Prostate Cancer; Urologic Oncology
Locations: EV, GB

Sidney Regalado, MD
Expertise: Interventional Radiology
Locations: EH, GB, HP, SK

Hayley Silver, MD
Expertise: Benign Prostate Hyperplasia; Kidney Stones; Male Bladder Symptoms; Vasectomy
Locations: EV, LV, SW

Anita Vasan Pattani, MD
Expertise: Internal Medicine; Hospice and Palliative Medicine
Locations: EV, GB, HP, SK

Mary Rhodes, MD
Expertise: Internal Medicine; Hospice and Palliative Medicine
Locations: EV, GB, HP, SK

Mark Sisco, MD
Division Head, Plastic Surgery
Expertise: Aesthetic Surgery; Breast and Body Surgery; Breast Reconstruction; Microsurgery
Location: NMB

For more information, visit northshore.org/cancer or call (847) 570-2112 or scan the QR code on the back cover.
### 2023 Physician Directory continued

**Breast Cancer Conferences**
NorthShore Evanston Hospital
Kellogg Room G868, Mondays, 7:30 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

**Colorectal Cancer Conferences**
NorthShore Evanston Hospital
Kellogg Room G868
2nd and 4th Fridays, 7 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

**Genitourinary Cancer Conferences**
NorthShore Evanston Hospital
Kellogg Room G868
1st and 3rd Fridays, 7 a.m.
NorthShore Glenbrook Hospital Videocast

**Gynecology Cancer Conferences**
NorthShore Evanston Hospital
Kellogg Room G868, Thursdays, 7 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

**Head and Neck Cancer Conferences**
NorthShore Evanston Hospital
Kellogg Room G868
1st and 3rd Thursdays, 8 a.m.

**Hematology/Pathology Conferences**
NorthShore Evanston Hospital
Kellogg Room G868, Tuesdays, 8 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

**Hepatic Biliary Pancreatic Cancer Conferences**
NorthShore Evanston Hospital
Kellogg Room G868, Tuesdays, 6:30 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

**Molecular Oncology Conferences**
NorthShore Evanston Hospital
Kellogg Room 4818, 1st Friday, 7 a.m.

**Neuro-Oncology Cancer Conferences**
NorthShore Evanston Hospital
Kellogg Room G868
2nd and 4th Wednesdays, 7:30 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

**Sarcoma/Melanoma Conferences**
NorthShore Evanston Hospital
Kellogg Room G868
1st and 3rd Wednesdays, 8 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

**Thoracic Cancer Conferences**
NorthShore Evanston Hospital
Kellogg Room G868, Tuesdays, noon
NorthShore Glenbrook and Highland Park Hospitals Videocast

---

Katharine Wailen Su, MD
Expertise: Lung Cancer; Esophageal Cancer; Benign Esophageal Disease; Paraesophageal Hernias; Mediastinal Masses; Diseases of Chest Wall and Pleura; Minimally Invasive Surgery; Advanced Endoscopy/Bronchoscopy
Locations: EVK, NCH, SW

Auddie Sweis, MD
Expertise: Nasal and Sinus Surgery; Endoscopic Skull Base Surgery
Locations: LB, SKM, SW

Mark Talamonti, MD
Department Chair, Surgery
Expertise: Gastrointestinal Surgical Oncology; Pancreatic Cancer; Benign and Malignant Liver Tumors; Neuroendocrine Tumors; Foregut Cancers of the Esophagus; Sarcoma
Location: EVK

Leslie Mendoza Temple, MD
Medical Director; Integrative Medicine
Expertise: Integrative Medicine
Location: GP

Christopher Trevino, MD
Expertise: Neuro-Oncology
Locations: EV, EVK, GBK

Michael Ujiki, MD
Vice Chair for Clinical Affairs, Gastrointestinal and General Surgery
Expertise: Minimally Invasive Surgery; Esophageal Surgery; Gastric Surgery; Bariatric Surgery; Flexible Endoscopy; Gallbladder Surgery
Locations: EV, GB

Elaine Lee Wade, MD
Expertise: Breast Cancer
Location: GBK

James Spitz, MD
Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancers; Advanced Lower Endoscopy
Locations: GB, HP4, VH

Amy Wang, MD
Expertise: Benign and Malignant Hematology
Location: EVK

K.T. Weber, MD
Expertise: Minimally Invasive Colon and Rectal Surgery
Locations: GB, SK, SW

Lauren Wiebe, MD
Expertise: Palliative Medicine; GI Oncology
Locations: EV, EVK, GB, GBK, HP, NCH, SK

Ricky Wong, MD
Expertise: Deep Brain and Vagal Nerve Stimulators; Brain and Skull Base Tumors; Pituitary Tumors; Cerebral Aneurysms; Arteriovenous Malformation (AVM); Trigeminal Neuralgia
Locations: EVK, NCH

Katherine Yao, MD
Vice Chair, Research and Development
Department of Surgery
Expertise: Breast Cancer, Breast Health; Breast Disease and Surgery
Locations: EV, GB

Andrew Zelby, MD
Expertise: Pituitary Tumors
Location: LV

Elaine Lee Wade, MD
Expertise: Breast Cancer
Location: GBK

Jason Waldinger, mD
Division Head, Dermatology
Expertise: General Dermatology; Skin Cancer
Location: LB

Lauren Wiebe, mD
Expertise: Palliative Medicine; GI Oncology
Locations: EV, EVK, GB, GBK, HPH, VH

Amy Wang, mD
Expertise: Benign and Malignant Hematology
Location: EVK

Thomas (T.J.) Smith, MD
Expertise: Breast Cancer; Breast Health; Breast Disease and Surgery
Locations: SK, SW

Alan Smookler, MD
Division Head, Palliative Care
Expertise: Internal Medicine; Geriatrics; Hospice and Palliative Medicine
Locations: EV, GB, HP, NCH, SK

K.T. Weber, mD
Expertise: Minimally Invasive Colon and Rectal Surgery
Locations: GB, SK, SW

Christopher Trevino, mD
Expertise: Neuro-Oncology
Locations: EV, EVK, GBK

K.T. Weber, mD
Expertise: Minimally Invasive Colon and Rectal Surgery
Locations: GB, SK, SW

---

For more information, visit [northshore.org/cancer](http://northshore.org/cancer), call (847) 570-2112 or scan the QR code on the back cover.
Locations

Evanston Breast Center (EVB)
2650 Ridge Avenue, Evanston, IL 60201

Evanston Hospital (EH)
2650 Ridge Avenue, Evanston, IL 60201

Evanston Kellogg Cancer Center (EVK)
2650 Ridge Avenue, Evanston, IL 60201

Evanston Specialty Suites (EV)
1000 Central Street, Evanston, IL 60201

Glenbrook Breast Center (GBB)
2050 Pfingsten Road, Suite 130
Glenview, IL 60026

Glenbrook Hospital (GBH)
2100 Pfingsten Road, Glenview, IL 60026

Glenbrook John and Carol Walter Ambulatory Care Center (GB)
2180 Pfingsten Road, Glenview, IL 60026

Glenbrook Kellogg Cancer Center (GBK)
2180 Pfingsten Road, Suite 1000
Glenview, IL 60026

Glenbrook Medical Building (GBM)
2050 Pfingsten Road, Suite 128
Glenview, IL 60026

Glenview Park Center (GP)
2400 Chestnut Avenue, Glenview, IL 60026

Gurnee Ambulatory Care Center (GR)
7900 Rollins Road, Gurnee, IL 60031

Highland Park Ambulatory Care Center (HPS)
757 Park Avenue West
Highland Park, IL 60035

Highland Park Breast Center (HPB)
777 Park Avenue West, Suite B400
Highland Park, IL 60035

Highland Park Hospital (HPH)
777 Park Avenue West, Room 1260
Highland Park, IL 60035

Highland Park Kellogg Cancer Center (HPK) — Ellen Marks Ambulatory Care Center
757 Park Avenue West, Suite 1810
Highland Park, IL 60035

Highland Park Medical Building (HP)
767 Park Avenue West, Suite B100
Highland Park, IL 60035

Lake Bluff Medical Building (LB)
71 Waukegan Road, Suite 700
Lake Bluff, IL 60044

Lakeview Medical Group (LV)
3122 N. Ashland Avenue
Chicago, IL 60657

Mount Prospect Medical Building (MP)
1329 Wolf Road, Mount Prospect, IL 60056

Northbrook Medical Building (NMB)
501 Skokie Boulevard
Northbrook, IL 60062

NorthShore Medical Group (SKM) — Skokie
9933 Woods Drive, Suite 200
Skokie, IL 60077

Northwest Community Healthcare (NCH)
880 West Central Road, Suite 4100
Arlington Heights, IL 60005

Skokie Ambulatory Care Center (SK)
9650 Gross Point Road, Suite 3000
Skokie, IL 60076

Skokie Medical Group (SKM)
9669 Kenton Avenue, Suite 206
Skokie, IL 60076

Swedish Hospital (SW)
5140 N. California Avenue
Chicago, IL 60625

Vernon Hills Specialty Suites (VH)
225 North Milwaukee Avenue
Vernon Hills, IL 60061

Wilmette Medical Office (WM)
1515 Sheridan Road, Suite 31A
Wilmette, IL 60091

For more information, visit northshore.org/cancer or call (847) 570-2112 or scan the QR code on the back cover.
2023 Cancer Committee

**Chairman**

Seth Krantz, MD  
Division Head, Thoracic Surgery  
Kellogg Cancer Center

**Cancer Liaison Physician**

Monika Krezalek, MD  
Director, Rectal Cancer Program

**Ancillary Membership**

Kim Cholewa, BSN  
Clinical Nurse Manager,  
5S Earle

Jamie Feld, MS/MPH, RN  
Oncology Accreditation and Quality Coordinator

Nancy Flowers, LCSW, MSW  
Psychosocial Services Coordinator

Kiley Telles Gregory, RDN, LDN  
Oncology Nutrition

Rachel Hollander  
Public Relations

Sharon Huginnie  
Senior Applications Analyst I  
Epic IP/HOV Team  
Health Information Technology

Elizabeth Kacel, PhD  
Clinical Psychologist

Kaitlyn Keen  
American Cancer Society

Aviva Matanky, RN, OCN  
Clinical Nurse Manager,  
Evanton Kellogg Cancer Center

Rachel Mees, MBA  
Cancer Program Administrator,  
Medical Group  
Kellogg Cancer Center

**Physician Membership***

Bruce Brockstein, MD  
Medical Director,  
Kellogg Cancer Center  
Head, Division of Hematology/Oncology  
Kellogg-Scanlon Chair of Oncology

Carolina Soto Chervin, MD

David Grinblatt, MD  
Medical Director, Cell Therapy

Elena Moore, MD

Kristian Novakovic, MD

Ajit Paintal, MD

Catherine Pesce, MD  
Division Head, Surgical Oncology

Nicklas Pfanzelter, MD  
Clinical Research Coordinator  
Quality Improvement Coordinator

Vathsala Raghavan, MD  
Director, Myra Rubenstein Weis Living in the Future (LIFE) Cancer Survivorship Program  
Survivorship Program Coordinator

Poornima Saha, MD

Georgia Spear, MD  
Section Head, Breast Imaging

Lauren Wiebe, MD

**Physician Membership***

*All academic affiliations are with the University of Chicago Pritzker School of Medicine

Sabina Omercajic, MS, CCRP  
Outreach Coordinator

Anisha Patel, APN  
Clinical Coordinator,  
MRW Living in the Future (LIFE) Cancer Survivorship Program

Dipale Patel, PharmD  
Senior Director, Oncology Pharmacy

Kyle Pietro  
Clinical Coordinator,  
Oncology Support Services,  
Kellogg Cancer Centers

Shayna Purcell, MS, CGC  
Medical Genetics

Amanda Schell, MS, OTR/L  
Rehabilitation Services

Frank Soucek, MSN, MBA, RN, NE-BC  
Clinical Director, Kellogg Cancer Center

Debra Ziegler, MLIS, CTR  
Cancer Registry Quality Coordinator  
Cancer Conference Coordinator

A publication of the Office of  
Corporate Communications

PHOTOGRAPHY: Jon Hillenbrand

WRITER: Susan J. White